Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 2/2003

Content (12 Articles)

Original Article

Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer

S. Urien, P. Fumoleau, M. Campone, P. Kerbrat, J. Bonneterre, P. Fargeot, R. Deporte-Fety

Original Article

Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics

Vinicius de Lima Vazquez, O. Anthony Stuart, Faheez Mohamed, Paul H. Sugarbaker

Original Article

A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies

A. Thalasila, Elizabeth Poplin, J. Shih, Dmitri Dvorzhinski, T. Capanna, S. Doyle-Lindrud, S. Beers, S. Goodin, Eric Rubin, Robert S. DiPaola

Original Article

Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer

Yasuhide Yamada, Kuniaki Shirao, Ichinosuke Hyodo, Yasuaki Arai, Tadamichi Denda, Tomonori Ambo, Atsushi Ohtsu

Original Article

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

Daniela Meco, Tina Colombo, Paolo Ubezio, Massimo Zucchetti, Marco Zaffaroni, Anna Riccardi, Glynn Faircloth, Jimeno Jose, Maurizio D'Incalci, Riccardo Riccardi

Original Article

Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats

Steven M. Musser, Merrill J. Egorin, Eleanor G. Zuhowski, Deborah R. Hamburger, Robert A. Parise, Joseph M. Covey, Kevin D. White, Julie L. Eiseman

Original Article

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study

Michela Donadio, Mara Ardine, Alfredo Berruti, Giuliana Ritorto, Elena Fea, Marinella Mistrangelo, Zaira Coccorullo, Paola Bergnolo, Alessandro Comandone, Oscar Bertetto

Original Article

Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study

Ross A. Soo, Hong L. Lim, Ling Z. Wang, How S. Lee, Michael J. Millward, Lay T. Tok, Soo C. Lee, Manfred Lehnert, Boon C. Goh

Original Article

Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay

Daniel L. Gustafson, Michael E. Long, Joseph A. Zirrolli, Mark W. Duncan, Scott N. Holden, A. Scott Pierson, S. Gail Eckhardt

Original Article

Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide

Patricia E. Schroeder, Peter Buhl Jensen, Maxwell Sehested, Kenneth Francis Hofland, Seppo W. Langer, Brian B. Hasinoff

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine